Literature DB >> 3026674

Enhancement of etoposide-induced cytotoxicity by cyclosporin A.

R Osieka, S Seeber, R Pannenbäcker, D Soll, P Glatte, C G Schmidt.   

Abstract

Following the clinical observation of enhanced antineoplastic action of etoposide in the presence of cyclosporin A (CyA), we investigated this drug interaction in several in vitro and in vivo tumor systems. Macromolecular DNA damage induced by etoposide at drug levels comparable to plasma AUC values achieved in patients was increased not only in leukemic peripheral blood cells from patients but also in mononuclear peripheral blood cells from a healthy donor. Intracellular retention of radioactivity from 3H-etoposide was increased by a factor of 1.5 at the most in the presence of CyA. The cytotoxicity of etoposide and adriamycin to L 1210 leukemic cells was clearly enhanced, whereas CyA had no effect on the action of cisplatin or ionizing irradiation. At CyA blood levels not exceeding 1.44 microgram/ml, increased tumor inhibition of etoposide was observed in a human embryonal cancer xenograft, but there was also higher lethality in normal mice. We conclude from our own data and from other recent findings that with respect to chemosensitization the effects of CyA resemble those of calcium channel blockers or anticalmodulin agents. In contrast to calcium channel blockers, however, adequate plasma levels of CyA can well be achieved in patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3026674     DOI: 10.1007/BF00273385

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Interaction of cyclosporin A with antineoplastic agents.

Authors:  O Kloke; R Osieka
Journal:  Klin Wochenschr       Date:  1985-10-15

2.  Effects of cytosine arabinoside on the cell viability and uptake of deoxypyrimidine nucleosides in L5178Y cells.

Authors:  M Y Chu; G A Fischer
Journal:  Biochem Pharmacol       Date:  1968-05       Impact factor: 5.858

Review 3.  Calmodulin.

Authors:  W Y Cheung
Journal:  Sci Am       Date:  1982-06       Impact factor: 2.142

4.  Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns.

Authors:  T Tsuruo; H Kawabata; N Nagumo; H Iida; Y Kitatani; S Tsukagoshi; Y Sakurai
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Phase I study of vinblastine and verapamil given by concurrent iv infusion.

Authors:  A B Benson; D L Trump; J M Koeller; M I Egorin; E A Olman; R S Witte; T E Davis; D C Tormey
Journal:  Cancer Treat Rep       Date:  1985 Jul-Aug

6.  Induction of interleukin 2 messenger RNA inhibited by cyclosporin A.

Authors:  J F Elliott; Y Lin; S B Mizel; R C Bleackley; D G Harnish; V Paetkau
Journal:  Science       Date:  1984-12-21       Impact factor: 47.728

7.  Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

8.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

Authors:  L M Slater; P Sweet; M Stupecky; S Gupta
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

9.  Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes.

Authors:  P M Colombani; A Robb; A D Hess
Journal:  Science       Date:  1985-04-19       Impact factor: 47.728

10.  Continuous infusion versus intermittent bolus injection of bleomycin in a human embryonal testicular cancer xenograft.

Authors:  R Osieka; P Glatte; C G Schmidt
Journal:  Cancer Treat Rep       Date:  1984-05
View more
  14 in total

1.  Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour.

Authors:  W Van de Vrie; R L Marquet; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor.

Authors:  E Friche; P B Jensen; N I Nissen
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour.

Authors:  W Van de Vrie; E E Gheuens; N M Durante; E A De Bruijn; R L Marquet; A T Van Oosterom; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Cyclosporin A potentiation of VP-16: production of long-term survival in murine acute lymphatic leukemia.

Authors:  L M Slater; J Cho; M Wetzel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 5.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

6.  The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat.

Authors:  W Van de Vrie; A M Jonker; R L Marquet; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 7.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

8.  Mitomycin C cross-resistance induced by adriamycin in human ovarian cancer cells in vitro.

Authors:  K Mizuno; Y Furuhashi; O Maeda; M Iwata; T Misawa; M Kawai; T Kano; Y Tomoda
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA.

Authors:  M Dietel; I Herzig; A Reymann; I Brandt; B Schaefer; A Bunge; H J Heidebrecht; A Seidel
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

10.  Cyclosporin A and verapamil have different effects on energy metabolism in multidrug-resistant tumour cells.

Authors:  H J Broxterman; H M Pinedo; G J Schuurhuis; J Lankelma
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.